Immuron Ltd — Regulatory Filings 2016

Feb 3, 2016

==> picture [213 x 60] intentionally omitted <==

Immuron Receives $1.47M R&D Tax Concession Refund

4 February 2016, Melbourne, Australia: Immuron Limited (ASX:IMC) is pleased to announce that the Company has received a Research and Development Tax Concession Incentive cash refund of $1,469,763 for the 2015 Financial Year as part of the Australian Government’s Research and Development Incentive Program.

This refund reflects the Company’s $3.3M investment in Research and Development expenditure during the 2015 Financial Year on its various R&D programs surrounding its Travelan, Protectyn, NASH, ASH, and C. Difficile development programs.

Immuron CEO Mr Thomas Liquard commented:

“It’s fantastic that the Australian Government has programs such as the Research and Development Tax Concession Incentive refund to assist early biotechnology companies fund their ongoing research and development pipelines and advance promising programs.

These programs create jobs for many Australians who are not only directly involved in the biotechnology industry but also for those working in supporting industries, which benefits the whole Australian economy.”

• END -

==> picture [547 x 41] intentionally omitted <==

Company Contact:

Thomas Liquard Chief Executive Officer AUS Ph: +61 (0)3 9824 5254 thomasliquard@immuron.com

Immuron US Investor Relations:

Jon Cunningham RedChip Companies, Inc. US Ph: +1 (407) 644 4256, (ext. 107) jon@redchip.com

About Immuron:

Immuron Ltd (ASX: IMC; OTCQB: IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.

For more information visit: http://www.immuron.com/

Suite 1, 1233 High Street Armadale, Victoria AUSTRALIA 3143

www.immuron.com

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735

ABN: 80 063 114 045